Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication

Recruiting now · Not applicable

Conditions studied: Helicobacter Pylori Eradication

In brief

1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.

Key facts

Study ID

NCT06349486

Run by

Kaohsiung Medical University

People needed

390

Starts

2023-11-28

Expected to finish

2026-12-31

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• (1) At least 18 years old. (2) Subjects infected with Helicobacter pylori.

You may not qualify if…

• Those who have ever received Helicobacter pylori sterilization treatment.
• Those who are allergic to the drugs used in this research.
• Those who have had stomach surgery.
• Those with severe liver cirrhosis or uremia or malignant tumors.
• Women who are pregnant or breastfeeding.

Where it is running

• Kaohsiung Medical University Hospital — Kaohsiung City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.